Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) revealed yesterday evening that its Board of Directors has chosen Dr. Richard Glickman, the biotech firm’s founder and Chairman, …
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) announced its Board of Directors has appointed Dr. Richard M.
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) announced that it has selected Worldwide Clinical Trials as its Clinical Research Organization (CRO) for the AURORA Phase 3 …
FBR Capital analyst Vernon Bernardino was out pounding the table on Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) Wednesday, reiterating an Outperform rating and price target of $9.00, which …
FBR analyst Vernon Bernardino came out with some commentary on Aurinia Pharmaceuticals Inc (NASDAQ:AUPH), after the drug maker announced it received meeting minutes for …
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) announced that it has received the final End of Phase II (EOP2) meeting minutes from the U.S.
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) announced the appointment of Lorin Jeffry “Jeff” Randall to its board of directors and Chairman of the Audit Committee. …
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) highlighted additional findings from its global Phase IIb AURA study of voclosporin in the treatment of lupus nephritis (LN). …
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) announced that it has entered into a Controlled Equity Offering Sales Agreement with Cantor Fitzgerald & Co. (“Cantor”) pursuant …
In a research report issued Thursday, FBR analyst Vernon Bernardino reiterated an Outperform rating on shares of Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) with a price …
